Drug intelligence / Profile preview

Yishengukang granules

Development stage: Unknown
Lead developer: Guangzhou University of Chinese Medicine
Administration: Oral

Overview

Yishengukang granules is a Traditional Chinese Medicine (TCM) herbal formulation developed for the treatment of cancer-related somatic pain, particularly in patients exhibiting the kidney-deficiency and blood-stasis syndrome. The formula is designed to tonify the kidney, strengthen bones, and invigorate blood circulation to alleviate pain. In clinical trials, it is evaluated as an adjuvant therapy to opioid analgesics like oxycodone to enhance pain control, improve quality of life, and potentially reduce the required opioid dosage. It was developed by researchers led by Qinglin Zhang at the First Affiliated Hospital of Guangzhou University of Chinese Medicine.

Other names: Yishengukang decoctionYishengukang Keli益肾骨康颗粒

Beyond the preview

Go deeper on Yishengukang granules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Yishengukang granules.

Explore the full profile